Latest news for Fincera (OTC:YUANF) Stock

Fincera

Fincera Inc provides web-based financing and e-commerce services for small and medium-sized businesses in China. Its services are small business lending, B2B payment solutions and e-commerce platforms and its products include CeraPay, CeraVest, TrueShip and AutoChekk. The company operates in Internet-based Business, Hotel Business, Office Leasing, and Corporate. The Internet-based Business generates maximum revenue for the company.

News

Intraday Update

Markets

Movers

Trading Ideas

ACSAY

ALLO

AMHPF

AMSC

APRN

APTS

ARCB

ARCH

AVGR

BCII

BKLRF

BRID

BRTX

BTUMF

CDZI

CEIX

CLDT

CNDT

CONN

CORE

CRWOY

China Shenhua Energy Unsponsored representing A shares

CSUAY

CTTMF

CVGI

DIGP

DNOW

DTNOF

EGLE

ELGX

ENTA

FLMN

FOSL

FRBK

FSAM

GALT

GLBS

GLNG

GLOP

GMLP

GOOS

HAYN

INCY

IPWG

ISUZY

ITAYY

JFIN

JNPR

KSRYY

LGYV

LNGLY

LQDT

LTMCF

LTRPA

MFCSF

MNOV

MNRO

MOBQ

METALLIS RESOURCES INC by Metallis Resources, Inc.

MTLFF

MYSZ

NDBKY

NEPT

NGVT

NHTC

NOVN

NTEC

OGSM

OMER

PAGP

PCFBY

PDNLA

PGAS

Stocks That Hit 52-Week Lows On Friday

Movers & Shakers

General

ADGO

AEMD

AFOM

AFTM

AIGI

AMRH

ANIX

ANTH

APCDF

APDN

AQMS

AVMR

BBLKF

BKPPF

BLOZF

BNFT

BRVVF

CDXI

CFPUF

CORV

CWGL

CXRXF

DESTQ

DMSI

DRRSF

DXBRF

EFIR

EFSH

ENZC

ETFLF

FAMI

FCUUF

FEIM

FNGR

GIGA

GRST

GTIM

GXXM

HIPH

HSEEF

HVBTF

INAP

ISWH

KOSCF

KPAY

LOVE

LPCN

MARA

MDFZF

MJGCF

MOSC

MPCIY

MSPC

MYRLF

NUBEVA TECH LTD ORD by Nubeva Technologies Ltd.

NBVAF

NIMU

NTTHF

PHVAF

PNWRF

PPSI

PSIX

PWRMF

RMBL

RTMAF

RVRA

SEDO

SGBX

SINO

SNNA

SPVNF

STTH

TLGT

TRAGF

TRHC

TTTSF

UBQU

VCSY

VIBI

VRTHF

WTER

YUANF

MCARY

AMTCQ

Fincera Inc

Boeing Calls New Proposal "Best And Final Offer" To Resolve Machinists Strike

Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.
The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">Gilead Unveils &#8216;Remarkable Outcomes&#8217; From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections</a>.
The <a target="_blank" href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due" rel="noreferrer noopener">affected</a> product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.
Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.
The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.
Gilead has reported no adverse events associated with this recall to date.
Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.
Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.
In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they <a target="_blank" href="https://www.benzinga.com/general/biotech/21/12/24452924/gilead-recalls-two-lots-of-remdesivir-due-to-presence-of-glass-particulates" rel="noreferrer noopener">contained glass particulates</a>.
In the second quarter of 2024, Veklury&nbsp;sales decreased 16% year over year to $214 million, primarily due to lower rates of <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">COVID-19-related hospitalizations</a>.
Price Action: GILD stock is down 0.05% at $83.90 at last check Monday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" target="_blank" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.</li>
</ul>

Biotech

Equities

Large Cap

Health Care

GILD

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares are trading higher Monday. Here&#8217;s <a href="https://www.benzinga.com/markets/asia/24/09/40986319/chinese-stocks-defy-bidens-auto-import-ban-concerns-rally-to-4-month-highs-as-central-bank-unexpecte">what you need to know</a>.
What to Know: Alibaba&#8217;s cloud computing unit partnered with Nvidia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance autonomous driving for Chinese EV makers, including Li Auto, Great Wall Motor and ZEEKR. This partnership integrates Alibaba&#8217;s Qwen large language models (LLMs) with Nvidia&#8217;s Drive AGX Orin platform, improving in-car AI capabilities. This move may be seen as strategic, especially as China grapples with U.S. sanctions restricting access to advanced semiconductor chips, which impact both Nvidia and Alibaba.
Market Context: The People's Bank of China (PBoC) recently slashed key interest rates and injected liquidity into the banking system, boosting investor confidence and contributing to a broader rally in Chinese stocks. The rate cuts are part of efforts to stimulate China&#8217;s economy ahead of its National Day Holiday.
BABA Price Action: BABA is trading at $90.05, reflecting a 1.99% gain according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-1024x530.png" alt="" class="wp-image-561642" style="width:485px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40987155/mullen-automotives-bollinger-motors-powers-up-first-customer-ready-b4-electric-truck-rolls-off-t">Mullen Automotive&#8217;s Bollinger Motors Powers Up: First Customer-Ready B4 Electric Truck Rolls Off The Line In Michigan</a></li>
</ul>
Photo courtesy: Alibaba INC.

BABA

NVDA

Alibaba Shares Are Trading Higher: What's Going On

Orgenesis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares are trading lower by 21% to 40 cents during Monday&#8217;s session after the company announced that its Board of Directors has approved a <a href="https://www.benzinga.com/pressreleases/24/09/g40976804/orgenesis-announces-reverse-stock-split">1-for-10 reverse stock split</a>, effective at 5:00 pm ET on September 24.
Orgenesis says this move aims to meet Nasdaq&#8217;s minimum $1.00 bid price requirement. The stock will continue trading under the symbol &#8220;ORGS&#8221; on a split-adjusted basis starting September 25. 
The reverse split will reduce the number of outstanding shares from 47.7 million to approximately 4.77 million, while stockholders&#8217; ownership percentages remain unchanged. 
The company also announced that fractional shares will be paid out in cash based on the closing price on September 24.
Read Also: <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">Qualcomm Takeover Of Intel Is &#8216;Logically Unlikely&#8217; In Face Of Regulatory Challenges, Analyst Says</a>
<h2 class="wp-block-heading">Should I Sell My ORGS Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Orgenesis have decreased by 29.34% in the past year. An investor who bought shares of Orgenesis at the beginning of the year would take a loss of $0.05 per share if they sold it today. The stock has fallen 37.67% over the past month, meaning an investor who bought shares on Aug. 1 would see a capital loss of $0.33.
Orgenesis shares have an all-time high of $5.02, representing 1045.86% upside from current levels.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ORGS has a 52-week high of $1.08 and a 52-week low of $0.25.

ORGS

Why Orgenesis (ORGS) Stock Is Down 23% Today

Masimo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 8.5% loss over the past four weeks.
The sharp upsurge in Masimo&#39;s shares can be attributed to the surprising news regarding the company&#39;s newly elected Board of Directors. On Sept. 19, per a public statement issued from Politan, activist investor Quentin Koffey, and his Politan Capital Management group&#39;s proposed candidates, both won election to the two available Board seats of Masimo. This guarantees that the new independent directors now have a control of the Board. On Sept. 20, the share price of MASI surged as the investors continued to celebrate the news in a positive view that the new Board is likely to be more conscious of and responsive to the investors.
This medical technology company is expected to post quarterly earnings of $0.84 per share in its upcoming report, which represents a year-over-year change of +33.3%. Revenues are expected to be $501.93 million, up 4.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Masimo, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy).
Masimo is part of the Zacks Medical - Instruments industry. CVRx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvrx#NASDAQ">CVRX</a>), another stock in the same industry, closed the last trading session 1.5% lower at $9.11. CVRX has returned 10.9% in the past month.
For CVRx, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.45. This represents a change of -4.7% from what the company reported a year ago. CVRx currently has a Zacks Rank of #3 (Hold).
<a href="https://www.zacks.com/stock/news/2339653/masimo-masi-surges-8-7-is-this-an-indication-of-further-gains?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_3%-2339653">To read this article on Zacks.com click here.</a>

Earnings

Mid Cap

Small Cap

Analyst Ratings

Tech

CVRX

MASI

Masimo Surges 8.7%: Is This an Indication of Further Gains?

Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading lower by 2.0% to $55.17 Monday afternoon. The stock is pulling back after rallying last week following the news of the Federal Reserve&#8217;s unexpected <a href="https://www.benzinga.com/markets/equities/24/09/40965372/fed-delivers-large-interest-rate-cut-in-bid-to-sustain-labor-market-stocks-gold-set-new-record-h">50-basis-point rate cut</a>.
Wells Fargo&#8217;s sensitivity to interest rate changes and investor speculation about the short-term effects on profitability has caused the stock to be volatile in recent sessions. 
What Happened: Last week&#8217;s larger-than-expected cut lowered the federal funds rate to a range of 4.75% to 5%, which was perceived as a positive development for Wells Fargo. Banks like Wells Fargo typically benefit from lower short-term borrowing costs, as they can access cheaper funding and potentially increase their net interest margins in the near term. 
Additionally, lower interest rates tend to stimulate borrowing by consumers and businesses, which could lead to increased loan demand and higher interest income for Wells Fargo. This potential for immediate growth in lending and profitability likely contributed to the stock&#8217;s initial rise, as investors anticipated a more favorable environment for the bank.
Read Also: <a href="https://www.benzinga.com/insights/options/24/09/40985016/what-the-options-market-tells-us-about-wells-fargo">What The Options Market Tells Us About Wells Fargo</a>
Furthermore, the Federal Reserve&#8217;s statement that inflation was moving sustainably toward 2% added to the market's confidence. As inflation concerns eased, the economic outlook seemed more stable, which would benefit Wells Fargo's business, as consumer and business confidence is critical for maintaining strong lending activity. 
The prospect of additional rate cuts, as indicated by the Fed's dot plot, suggested a longer period of easier monetary policy, further fueling the short-term enthusiasm for Wells Fargo stock.
What Else: Monday&#8217;s subsequent pullback could reflect a more cautious reassessment of the bank&#8217;s long-term outlook. Although lower interest rates reduce short-term borrowing costs, they also typically lead to a decline in long-term rates. This could compress Wells Fargo&#8217;s net interest margins, as the bank earns less on long-term loans while still facing lower yields on its assets. 
Over time, the bank&#8217;s ability to generate income from interest on loans could be hampered in a prolonged low-rate environment, reducing profitability. Investors likely became concerned that while the initial rate cut seemed positive, the extended path of rate reductions might hurt Wells Fargo's ability to sustain its earnings over the longer term.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a>
Additionally, the Federal Reserve's updated economic projections painted a less favorable picture for future growth. The downward revision in real GDP growth forecasts, coupled with higher unemployment projections through 2026, signaled a weakening economy. 
This raised concerns about potential loan defaults, as higher unemployment often leads to increased credit risk. Wells Fargo, which holds large portfolios of consumer and business loans, could face rising delinquencies and losses in a slower economy. 
The bank&#8217;s exposure to consumer credit, mortgages and commercial loans means that an economic downturn or a prolonged period of sluggish growth would directly impact its earnings.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
By now you're likely curious about how to participate in the market for Wells Fargo &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Wells Fargo, which is trading at $55.21 as of publishing time, $100 would buy you 1.81 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WFC has a 52-week high of $62.55 and a 52-week low of $38.38.

What's Going On With Wells Fargo (WFC) Stock?

Boeing Increases General Wage By 30%, Boosts 401(K) Match To 100% Of First 8% Of Pay, And Raises Ratification Bonus To $6,000 In IAM Labor Negotiations

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">sharp stock decline</a> after Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) mid-stage data on its obesity drug.
Andres Maldonado of H.C. Wainwright reiterated a Buy rating for Corbus with an $80 price target, highlighting that Novo's recent challenges with monlunabant, a drug targeting the same receptor as Corbus&#8217; CRB-913, should not impact the latter's potential. The stock currently trades below the $20 mark.
Maldonado<a href="https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-corbus-pharmaceuticals-on-crb-913s-potential-and-holistic-pipeline-valuation?utm_source=benzinga.com&amp;utm_medium=referral"> stressed </a>that different drugs within the same class could exhibit unique efficacy and safety profiles.&nbsp;
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Oppenheimer And Mizuho Double Down On Corbus' Pipeline</h3>
Oppenheimer also maintained a Buy rating, setting a price target of $88, focusing not only on CRB-913 but also on Corbus' broader assets, especially CRB-701.&nbsp;
Mizuho similarly recommended <a href="https://seekingalpha.com/news/4151904-mizuho-recommends-buying-corbus-following-its-drop-post-novos-obesity-data?utm_source=partner_&amp;utm_medium=referral&amp;feed_item_type=news">buying the dip</a>, viewing the recent 60% stock plunge as an overreaction.&nbsp;
The firm pointed to CRB-701's positive Phase 1 data and sees the company's valuation primarily tied to this Nectin-4-based ADC for cancer treatment, rather than the obesity drug alone.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk&#8217;s Cannabinoid-Based Weight Loss Drug Trial Disappoints</a>

Cannabis

Price Target

Reiteration

CRBP

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Fincera

News

Latest news for Fincera (OTC:YUANF) Stock

Friday, January 31, 2020

Friday, December 13, 2019